Bio

Ulla Hald Buhl, born 1964, a degree in health care administration from the University of Southern Denmark, a bachelor’s degree in nursing, and has completed the Board Leadership Masterclass at Copenhagen Business School. Hald Buhl has 25 years of experience in the biotech sector as a serial entrepreneur, founder and/or co-founder (Oncology Venture A/S, 2X Oncology Ltd., Cessatech A/S, Buhl Oncology ApS, CHOSA Oncology ApS and Aïda Oncology ApS) and has been involved in several IPOs (WntResearch AB, MPI A/S, Oncology Venture A/S, and Cessatech A/S) as well as two product approvals (Savene® and Belinostat®).

Ulla Hald Buhl’s other assignments include: managing director of Aïda Oncology ApS and Buhl Krone Holding ApS.

Ulla together with Peter hold 15 506 935 shares corresponding to approximately 24.7% of the shares in Rhovac after the merger.

Ulla Hald Buhl

COO & Board Member

Experience

  • Chief Operating Officer & Board Member, CHOSA Oncology

  • Managing Director, Aïda Oncology ApS

  • Founder & COO, Oncology Venture A/S

  • Director of Investor Relations & Communications, TopoTarget A/S

  • Founder, Buhl Oncology ApS

  • Co-founder, Cessatech A/S

Key Achievements

  • 25+ years of leadership experience in biotechnology and precision oncology

  • Co-founded and helped build multiple biotechnology companies

  • Led investor relations, corporate communications and operational strategy across publicly listed life science companies

  • Contributed to the successful development and commercialization of innovative oncology products

  • Extensive expertise in corporate operations, business development and company scaling